Amicus Therapeutics, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Amicus Therapeutics filed additional proxy materials to supplement its definitive proxy statement for the BioMarin merger, addressing multiple stockholder lawsuits and updating financial projections.
NASDAQ
Amicus Therapeutics provides preliminary unaudited financial results for 2025, showing robust product revenue growth ahead of its acquisition by BioMarin.
NASDAQ
BioMarin Pharmaceutical Inc. will acquire Amicus Therapeutics Inc. for $14.50 per share in an all-cash transaction, expanding its rare disease portfolio.
NASDAQ
Amicus Therapeutics has filed a definitive proxy statement with the SEC, signaling upcoming shareholder actions.
NASDAQ
Amicus Therapeutics is set to hold its 2025 Annual Meeting of Stockholders virtually on June 5, 2025, to vote on director elections, an equity incentive plan, auditor ratification, and executive compensation.
NASDAQ
Amicus Therapeutics has filed a definitive proxy statement with the SEC, signaling upcoming shareholder actions.
NASDAQ
Amicus Therapeutics is asking stockholders to approve an amended equity incentive plan to add 7,000,000 shares to the equity pool at the upcoming annual meeting.